Javascript must be enabled to continue!
1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
View through CrossRef
DA-1726 is a novel oxyntomodulin analogue preparing for phase I clinical trials for obesity. In this study, the pharmacological effect of DA-1726 compared to other competitor peptides was evaluated. DA-1726 showed superior efficacy compared to other glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist (Cotadutide; COTA) in reducing body weight (14.4% for DA-1726 and 6.4% for COTA vs. DIO control at 30 nmol/kg, p<0.05) and improving plasma glucose, insulin, and HOMA-IR (-91% for DA-1726 vs. -52% for COTA) in diet-induced obese mice. In addition, superior plasma triglyceride (TG) reduction and similar reduction of total cholesterol (T-CHO) compared to COTA were confirmed by DA-1726. These data suggested that the balanced dual agonist DA-1726 was superior to a GLP1R-biased dual agonist in metabolic effects. Meanwhile, enhanced glucagon action of GLP1R/GCGR dual agonists may increase the risk of hyperglycemia when GLP1R agonism is reduced. Thus, DA-1726 was injected for 3 weeks and glucose tolerance test was performed at 72-h after the last dosing. DA-1726 did not impair glucose tolerance even at minimal plasma concentrations during repeated dosing up to 100 nmol/kg. In the case of repeated dosing of 100 nmol/kg, the plasma drug concentration at 72-h after the final injection is similar to the concentration that induces about 50% activation of receptors under 4% human albumin condition. In a comparative study with a GLP1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist (Tirzepatide; TIR), DA-1726 showed a similar maximum efficacy on weight loss (31.2% for DA-1726 and 31.3% for TIR vs. DIO control, p<0.05). However, DA-1726 was more efficacious in improving plasma metabolic parameters such as glucose, TG, and T-CHO compared to TIR, indicating differential metabolic effects caused by GCGR agonism. Taken together, these data suggest that DA-1726 is a well-balanced GLP1R/GCGR dual agonist that effectively reduces body weight and glycemic control.
Disclosure
Y.Chae: None. I.Jung: None. T.Kim: None. S.Lee: None. M.Kim: Employee; Dong-A ST. H.Kim: None.
American Diabetes Association
Title: 1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
Description:
DA-1726 is a novel oxyntomodulin analogue preparing for phase I clinical trials for obesity.
In this study, the pharmacological effect of DA-1726 compared to other competitor peptides was evaluated.
DA-1726 showed superior efficacy compared to other glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist (Cotadutide; COTA) in reducing body weight (14.
4% for DA-1726 and 6.
4% for COTA vs.
DIO control at 30 nmol/kg, p<0.
05) and improving plasma glucose, insulin, and HOMA-IR (-91% for DA-1726 vs.
-52% for COTA) in diet-induced obese mice.
In addition, superior plasma triglyceride (TG) reduction and similar reduction of total cholesterol (T-CHO) compared to COTA were confirmed by DA-1726.
These data suggested that the balanced dual agonist DA-1726 was superior to a GLP1R-biased dual agonist in metabolic effects.
Meanwhile, enhanced glucagon action of GLP1R/GCGR dual agonists may increase the risk of hyperglycemia when GLP1R agonism is reduced.
Thus, DA-1726 was injected for 3 weeks and glucose tolerance test was performed at 72-h after the last dosing.
DA-1726 did not impair glucose tolerance even at minimal plasma concentrations during repeated dosing up to 100 nmol/kg.
In the case of repeated dosing of 100 nmol/kg, the plasma drug concentration at 72-h after the final injection is similar to the concentration that induces about 50% activation of receptors under 4% human albumin condition.
In a comparative study with a GLP1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist (Tirzepatide; TIR), DA-1726 showed a similar maximum efficacy on weight loss (31.
2% for DA-1726 and 31.
3% for TIR vs.
DIO control, p<0.
05).
However, DA-1726 was more efficacious in improving plasma metabolic parameters such as glucose, TG, and T-CHO compared to TIR, indicating differential metabolic effects caused by GCGR agonism.
Taken together, these data suggest that DA-1726 is a well-balanced GLP1R/GCGR dual agonist that effectively reduces body weight and glycemic control.
Disclosure
Y.
Chae: None.
I.
Jung: None.
T.
Kim: None.
S.
Lee: None.
M.
Kim: Employee; Dong-A ST.
H.
Kim: None.
Related Results
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
Glucagon regulates metabolic functions through the glucagon receptor (GCGR). Agonists as well as antagonists of GCGR are evaluated as treatments of diabetes and obesity. To underst...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
<b>Background and Purpose:</b> Periodontitis combines persistent inflammation with impaired periodontal regeneration. We investigated whether post-translational modific...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
Periodontitis is characterized by persistent inflammation and impaired periodontal regeneration, but the mechanism linking these processes remains unclear. Here, we identified a pa...
1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
DA-1726 showed superior weight loss efficacy compared to Semaglutide (SEMA) in DIO mice. In this following study, a dose-response of DA-1726 was evaluated to determine the maximum ...
2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management
2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management
DA-1726 is being prepared for obesity Phase 1 clinical trials following IND approval. Our study focuses on the pharmacological effects of this novel oxyntomodulin analogue, which h...
Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
Abstract
Abstract 421
Treatment of hematological malignancies, non-Hodgkins lymphoma in particular, has evolved greatly in the past decade with the ad...
A Comparison of Rusunawa A4 IPB Building Storey Shear using Seismic Code of SNI 1726-2002 and SNI 1726-2012
A Comparison of Rusunawa A4 IPB Building Storey Shear using Seismic Code of SNI 1726-2002 and SNI 1726-2012
Indonesia is a high-risk earthquake country. It passed by Pacific Ring of Fire and surrounded by Eurasian, Pacific, Philippines and Indo-Australian plates. Indonesia government has...
1894-P: Interruption of Glucagon Signaling Increases Pancreas Mass
1894-P: Interruption of Glucagon Signaling Increases Pancreas Mass
Interruption of glucagon signaling by glucagon receptor gene inactivation or treatment with a glucagon receptor blocking monoclonal antibody (GCGR-Ab) stimulates alpha cell prolife...

